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Background: Hemodialysis patients experience a wide variety of intermediate complications, 
such as anemia, hypertension and mineral bone disease (MBD). We aimed to assess the risk 
of death and hospital admissions as a function of the simultaneous attainment of different 
guideline targets (for hypertension, anemia and MBD) in a large European cohort of dialysis 
patients. 
Methods: EURODOPPS is part of the DOPPS international, prospective cohort study of 
adult, in-center hemodialysis patients for whom clinical data are extracted from medical 
records. In the present analysis, 6317 patients from seven European countries were included 
between 2009 and 2011. The percentages of patients treated according to the international 
guidelines on anemia, hypertension, and MBD were determined. The overall degree of 
guideline attainment was considered to be high if four or all five of the evaluated targets were 
attained, moderate if two or three targets were attained, and low if less than two targets were 
attained. Fully adjusted multivariate Cox models were used to investigate the relationship of 
target attainment with mortality and first hospital admission. 
Results: At baseline, the degree of target attainment was low in 1751 patients (28%), 
moderate in 3803 (60%) and high in 763 (12%). In the fully adjusted model using time-
dependent covariates, low attainment was associated with higher all-cause mortality (hazard 
ratio [95% confidence interval]: 1.19 [1.05–1.34]) and high attainment was associated with 
lower all-cause mortality (0.82 [0.68–0.99]). In a similar model that additionally accounted 
for death as a competing risk, low and high attainment were not associated with hospital 
admission. 
Conclusion: In a large international cohort of dialysis patients, we have shown that more 
stringent application of guidelines is associated with lower mortality.  
 




Chronic kidney disease (CKD) is a major global health problem, in view of its high 
prevalence and associated complications. [1] The number of deaths directly attributable to 
CKD rose by 36% between 1990 and 2013. [2] The progression of CKD is associated with an 
elevated incidence of serious complications, including cardiovascular disease, anemia and 
mineral bone disease (MBD). Hence, CKD patients should be screened for these 
complications and then be treated appropriately. Furthermore, reduction of the corresponding 
morbidity and mortality rates requires a multidisciplinary approach. 
Various international guidelines have focused on reducing the complications of CKD. 
[3],[4] In hemodialysis patients, we recently highlighted (i) a low overall level of guideline 
target attainment in Europe and (ii) substantial differences between European countries in this 
respect. [5] Indeed, hemodialysis patients experience various concomitant complications, such 
as MBD (including abnormalities of calcium, phosphate or parathyroid hormone (PTH)), 
anemia and hypertension. [6] Considering any of these conditions in isolation is inconsistent 
with the clinical situations that physicians encounter in practice. Most epidemiologic studies 
have sought to assess the prognostic value of a single complication, such as hypertension or 
hyperphosphatemia. [7] In contrast, there are few studies that focus on CKD-related metabolic 
complications as a whole and their  impact on hard outcomes. [8] 
We therefore sought to assess survival and hospitalization as a function of the degree 
of guideline target attainment (hypertension, anemia and MBD), using data from a large, 
prospective, European study of a cohort of adult in-center hemodialysis patients.  
METHODS 
Study population 
The DOPPS is an international, prospective study of a cohort of adult (aged 18 and 
over) in-center hemodialysis patients. The study is currently in its sixth phase (DOPPS 6). 
Details of the study’s design have been reported elsewhere. [9] The present analysis included 
6317 EURODOPPS participants from seven European countries (Belgium, France, Germany, 
Italy, Spain, Sweden and the UK) in DOPPS phase 4 (2009-2011). The study was approved 





We assessed data on five targets: blood pressure, and serum levels of phosphate, 
hemoglobin, PTH, and calcium. For each investigated parameter, the selected target ranges 
(extracted from the international KDOQI or KDIGO guidelines and (if available) the 
European Renal Best Practice guidelines at the time of the study (2009-2011)) are given in 
Table 1. For each patient, we calculated how many of the targets had been met and then 
graded the overall degree of target attainment. The overall degree of target attainment was 
considered to be high if 4 or 5 targets were attained, moderate if 2 or 3 targets were attained, 
and low if less than 2 targets were attained. Data on demographic parameters, comorbidities, 
laboratory test values and dialysis were extracted from the patients’ medical records at study 
entry. Follow-up information was obtained every 4 months and included laboratory 
measurements and dates of and diagnoses associated with patient hospitalization. Mortality 
data were collected continuously during the study follow-up period. [9], [10]  
 
Statistical analyses 
We used Cox proportional-hazards regression models with time-dependent covariates 
to relate all-cause mortality to the 4-month running values of overall target attainment in 
dialysis patients [11,12]. In order to account for death as a competing risk [13], we also used a 
Fine and Gray model to evaluate the association between the 4-month running values of 
overall target attainment and first hospital admission [14]. The time at risk ended upon death, 
first hospital admission, discharge from the facility (due to transfer or a change in the type of 
renal replacement therapy) plus 7 days, loss to follow-up, transplantation, or the end of the 
study phase (whichever occurred first).  
To check for reverse causality, the second last follow-up laboratory value for each 
target was used rather than the last assessment to define “target attainment” (time-lagged 
covariate). We used the second  last follow-up laboratory value because we thought that using 
the last assessment might lead (in some cases) to an evaluation of parameters in the “acute 
phase” of the disease and thus might overestimate the off-target patients. [12] The 
proportional hazard assumption was evaluated using Schoenfeld residuals. [11] Time to death 
and first hospital admission were analyzed without adjustment (Model 0), and with 
adjustment for age, gender, race (Caucasian vs. non-Caucasian), country, smoking status 
(active vs. former smoker), time on dialysis, single pool Kt/V, and body mass index. Model 2 
was additionally adjusted for the presence or absence of 13 comorbid conditions (the usual 
adjustment covariates used in DOPPS studies): diabetes mellitus, cancer (excluding skin), 
HIV, lung disease, psychiatric disorders, gastrointestinal bleeding, neurological disease, 
recurrent cellulitis, hypertension, congestive heart failure, cerebrovascular disease, coronary 
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heart disease, and other cardiovascular diseases. When studying the associations with 
individual targets and outcomes, we further adjusted for each target in a separate model 
(Model 3). Sensitivity analysis were performed excluding blood pressure target from the 
overall target attainment. We also calculated the variance inflation factor to examine 
multicollinearity between the predictors. 
The variance inflation factor was <4.0 for all predictors in the models used for both mortality 
and hospitalization analyses, which indicated that there was limited multicollinearity and thus 
did not warrant further investigation. 
Missing values for exposure and confounding variables were imputed by multiple 
imputation by chained equations in which 20 completed data sets were generated and 
analyzed with standard combination rules for multiple imputation. Each variable was used as 
a predictor in the imputation model. Variance inflation factor was calculated by taking the 
mean for the imputed results. We assumed that the data were missing at random.  
Our results are reported as the hazard ratio (HR) [95% confidence interval (CI)]. The 
threshold for statistical significance was set to p<0.05. All statistical analyses were performed 





Characteristics of the study population 
In the present analysis, 6317 hemodialysis patients from seven European countries were 
included between 2009 and 2011; this total comprised 300 (4.8%) incident patients (i.e. 
hemodialysis for 30 days or less) and 6017 (95.3%) prevalent patients (i.e. hemodialysis for 
over 30 days). The study population’s baseline demographic and clinical characteristics 
according to the overall degree of target attainment are summarized in Table 2. The mean ± 
standard deviation (SD) age was 65.5 ± 15.0. More than half of the patients were men (60.8%, 
n=3840), and the great majority of the patients were of Caucasian origin (93.4%, n=5898). 
About one third of the patients were diabetic (36.5%, n=2304), and 11.2% (n=708) were 
current smokers. At baseline, attainment of guidelines was considered to be low in 1751 
(27.7%) patients, moderate in 3803 (60.2%) and high in 763 (12.1%). On average, patients in 
the “high attainment” group were older, less likely to be active smokers, and had been on 
dialysis longer than patients in the “moderate attainment” and “low attainment” groups. There 
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were no other significant differences in dialysis characteristics or comorbidities according to 
the degree of target attainment.  
All-cause mortality 
The total number of person-years in the analysis of all-cause mortality was 9119.3 
(median (25th-75th percentile) follow-up time: 1.38 (0.68-2.27) years), during which time a 
total of 1328 patients died, the other 4989 patients are censored (3779 due to end of follow-up 
period, 499 due to transplantation, 55 due to transfer to other dialysis modality, 27 due to 
recovery renal function and 629 were lost to follow-up). 
 Table 3 shows the HRs for all-cause mortality according to the overall degree of guidelines 
target attainment. The proportional hazards assumption was met for all associations tested. In 
the fully adjusted model using time-varying covariates, a low degree of target attainment at 
baseline was associated with significantly higher all-cause mortality (HR [95%CI] = 1.19 
[1.05–1.34] (Table 3), whereas a high degree of target attainment was associated with 
significantly lower all-cause mortality (HR [95%CI] = 0.82 [0.68–0.99]). The decrease in HR 
as a function of the degree of target attainment appeared to be gradual (Supplementary Table 
1).  
For individual targets, anemia, failure to attain PTH targets and failure to attain calcium 
targets (excessively low or high values) was associated with increased mortality. In contrast, 
elevated blood pressure levels were associated with lower mortality (Supplementary Table 2). 
In a sensitivity analysis, exclusion of blood pressure target from the overall target confirmed 
that a low degree of overall target attainment was associated with worse survival (HR 
[95%CI] = 1.35 [1.21–1.51] (Supplementary Table 3). 
 
Hospitalization 
Over a median (25th-75th percentile) follow-up period of 6.6 (2.6-15.1) months, a total of 3695 
first hospital admissions were recorded, 342 patients died (competing event), the other 2278 
patients are censored (1602 due to end of follow-up period, 291 due to transplantation, 29 due 
to transfer to other dialysis modality, 18 due to recovery renal function and 338 were lost to 
follow-up). Supplementary Table 4 shows the results of a time-varying analysis (accounting 
for death as a competing risk) of the associations between the attainment of individual 
guideline targets and the first hospital admission. In the fully adjusted model, neither low nor 
high degrees of target attainment at baseline were associated with the risk of hospitalization 




In a large, representative population of hemodialysis patients in seven European 
countries, we assess survival and hospitalization as a function of the degree of guideline target 
attainment based on international guidelines for hypertension, anemia and CKD-MBD 
published during DOPPS phase 4 (2009-2011). A high overall degree of target attainment was 
independently associated with better survival, and this association increased gradually as a 
function of degree of target attainment.  
A key feature of the present analysis is that we evaluated several different CKD-
related metabolic complications; this approach more closely mirrors clinical practice, where 
patients frequently display several complications concomitantly. Indeed, most epidemiologic 
studies have evaluated the association of a single complication or a single drug class on hard 
endpoints such as mortality. [15],[16] A global approach (i.e. simultaneously considering the 
various CKD-related metabolic complications and their respective associations on hard 
outcomes) is more relevant with regard to everyday clinical practice. Even though the 
parameters studied here constitute intermediate outcomes, they are important in a CKD 
setting and can be modulated using pharmacological therapy. Hence, this type of analysis is 
particularly relevant because clinical trials based on hard clinical outcomes are relatively 
infrequent in CKD patients. [17], [18] 
In the field of CKD, it is relatively difficult to draft detailed guidelines based on strong 
scientific evidence. This might affect the extent to which clinicians agree with and adopt a 
given guideline. [18] Even though the guidelines studied here may be based on relatively low 
levels of evidence, our present findings suggest that target attainment could be associated with 
significantly improve outcomes even if causal relationship can not be shown in this kind of 
analysis. In the present study, only 12% of the patients attained 4 or 5 targets, so there is 
definitely room for improvement in target attainment and outcomes across Europe. However, 
target attainment might face several obstacles. Indeed, certain patient characteristics might 
explain the poor target attainment in the 28% of patients in the “low attainment” group. In a 
patient with several comorbidities and a short life expectancy, one can presume that the 
attainment of clinical metabolic targets is not the nephrologist’s priority for care, and 
attainment may turn out to be very difficult or impossible. In contrast, for a young patient 
expecting to undergo kidney transplantation, attainment of clinical metabolic targets will be 
strongly pursued. Furthermore, target attainment is known to be associated with dialysis 
vintage, as patients need time to reach target levels. The current study cohort also included 
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incident patients and patients who had not been on hemodialysis for very long at the time of 
study enrollment, which may have reduced target attainment. Lastly, poor adherence to 
medications (and particularly phosphate binders) and dietary restrictions is frequent among 
hemodialysis patients [20,21,22,23]. 
In the present study, we found that high blood pressure levels were associated with 
lower mortality. This may be because low blood pressure levels reflect heart failure, the 
prevalence of which is high among patients with CKD [19]. This constituted a potential 
source of bias, since as patients with heart failure (characterized by low blood pressure) might 
have a higher risk of death. After excluding the blood pressure target from the overall target 
attainment, we observed a 35% increase in the risk of death in the low target attainment group 
versus the moderate target attainment group; hence, one could argue that inclusion of a blood 
pressure target dampens the influence on outcomes. 
The findings of the present study suggest that a more stringent application of guidelines is 
associated with lower mortality. How dialysis units might achieve these targets within their 
current care systems should be debated. In the US, the Centers for Medicare and Medicaid 
Services and commercial insurers use clinical performance measures (CPMs) to assess the 
quality of care [24]. In this quality incentive program, a portion of the payment made to a 
dialysis facility is linked to the latter’s CPMs. Furthermore, the publication of CPMs provides 
all stakeholders (including patients and physicians) information on performance quality that 
can be useful when selecting caregivers and facilities for referral and care. [24] However, not 
all countries operate quality incentive programs, and the latter’s impacts on guideline 
attainment at dialysis facilities have yet to be evaluated. 
The present study had several strengths: firstly, our analysis of hard outcomes usefully 
complements our previous report on the low overall degree of target attainment in 
EURODOPPS patients and the differences between European countries in this respect. [5] 
Secondly, we performed Cox analyses with time-varying covariates because a baseline 
analysis evaluates an effect at a single moment in time, which may not be of value from a 
clinical point of view. [23] In contrast, a time-varying covariate approach enables evaluation 
of any potential effects of target attainment and covariate changes over time. Some limitations 
merit consideration: firstly, this study was based on observational data, and patients were not 
randomized so no causal relationships can be inferred. Patients in the “higher guideline target 
attainment” were older and had been on dialysis for a longer time, so one cannot rule out a 
survival bias. Furthermore, residual cofounding can never be ruled out. A patient’s ability to 
attain guideline targets might also result from his/her general health status, which is difficult 
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to take into account in statistical models. Our analyses were extensively adjusted (e.g. for age, 
comorbidities, and country) to minimize the risk of residual cofounding. However, 
confounding by indication (inherent to the observational nature of the study) can not be 
accounted for in this kind of analysis. Indeed, the results of this study should be interpreted in 
light of this, as the physician may have been less stringent in adhering to guidelines in 
patients for whom he/she expected to have a poor survival. This may be a partial explanation 
for our findings. Secondly, we selected a set of biological variables that could be modulated 
by pharmacological agents and/or dietary restrictions and for which detailed data were 
collected in the DOPPS; however, also other variables not studied here might have had an 
impact on mortality and hospitalization. Other important guideline targets (such as functional 
vascular access) were not evaluated in the present study, although the single pool Kt/V was 
>1.2 and did not differ significantly when comparing the three groups (thus ruling out a 
potential under-dialysis issue). [24] Furthermore, we did not have data on malnutrition, 
achievement of dry weight, the frequency of intradialytic hypotension, and the level of 
ultrafiltration – all factors that might modulate outcomes in hemodialysis patients, were not 
available. Thirdly, we were unable to assess the patients’ adherence to treatment (including 
medications and dietary restrictions) – a factor that might have a major effect on target 
attainment.  
 
In conclusion, our analysis of data from a large cohort study of European hemodialysis 
patients showed that the attainment of targets according to international guidelines is 
associated with a lower risk of all-cause mortality.  
 
ACKNOWLEDGEMENTS 
This article was written by S.L., A.S., A.K., B.B., K.M., R.P., F.C., C.C., B.M.R., K.J.J, 
Z.A.M. on behalf of the EURODOPPS and the European Renal Association – European 
Dialysis and Transplant Association (ERA-EDTA) Registry which is an official body of the 
ERA-EDTA. The EURODOPPS Initiative is funded by the ERA-EDTA and the DOPPS 
Program. In turn, the DOPPS program is funded by Amgen, Kyowa Hakko Kirin, AbbVie 
Inc., Sanofi Renal, Baxter Healthcare, and Vifor Fresenius Medical Care Renal Pharma, Ltd. 
Additional support for specific projects and countries is also provided by the ERA-EDTA, 
Keryx Biopharmaceuticals, Inc., Merck Sharp & Dohme Corp., Proteon Therapeutics, 
Relypsa, and F. Hoffmann-LaRoche Ltd.; in Canada by Amgen, BHC Medical, Janssen, 
Takeda, Kidney Foundation of Canada (for logistics support); in Germany by Hexal, DGfN, 
 10 
Shire, WiNe Institute; for PDOPPS in Japan by the Japanese Society for Peritoneal Dialysis 
(JSPD). All support is provided without restrictions on publications. Grants are made to Arbor 
Research Collaborative for Health and not to individual investigators.  
S. Liabeuf’s clinical fellowships are provided by ERA-EDTA. The authors alone are 
responsible for the reporting and interpretation of EURODOPPS data used in the publication 
and these reports do not necessarily represent the decisions or policies of the ERA-EDTA or 




1.  Mills KT, Xu Y, Zhang W, Bundy JD, Chen C-S, Kelly TN, et al. A systematic analysis of 
worldwide population-based data on the global burden of chronic kidney disease in 
2010. Kidney Int. nov 2015;88(5):950‑7.  
2.  Jager KJ, Fraser SDS. The ascending rank of chronic kidney disease in the global burden 
of disease study. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren 
Assoc. 11 févr 2017;  
3.  Verbeke F, Lindley E, Van Bortel L, Vanholder R, London G, Cochat P, et al. A European 
Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global 
Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in 
non-dialysis-dependent chronic kidney disease: an endorsement with some caveats for 
real-life application. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren 
Assoc. mars 2014;29(3):490‑6.  
4.  KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic 
Kidney Disease. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. 
Kidney International  Suppl. 2013;1‑150.  
5.  Liabeuf S, Van Stralen KJ, Caskey F, Tentori F, Pisoni RL, Sajjad A, et al. Attainment of 
guideline targets in EURODOPPS haemodialysis patients: are differences related to a 
country’s healthcare expenditure and nephrologist workforce? Nephrol Dial Transplant 
Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 5 janv 2017;  
6.  Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet Lond 
Engl. 22 nov 2016;  
7.  Hruska KA, Mathew S, Lund R, Qiu P, Pratt R. Hyperphosphatemia of chronic kidney 
disease. Kidney Int. juill 2008;74(2):148‑57.  
8.  Port FK, Pisoni RL, Bragg-Gresham JL, Satayathum SS, Young EW, Wolfe RA, et al. DOPPS 
estimates of patient life years attributable to modifiable hemodialysis practices in the 
United States. Blood Purif. 2004;22(1):175‑80.  
9.  Pisoni RL, Gillespie BW, Dickinson DM, Chen K, Kutner MH, Wolfe RA. The Dialysis 
Outcomes and Practice Patterns Study (DOPPS): design, data elements, and 
methodology. Am J Kidney Dis Off J Natl Kidney Found. nov 2004;44(5 Suppl 2):7‑15.  
10.  Robinson BM, Port FK. Caring for dialysis patients: international insights from the 
Dialysis Outcomes and Practice Patterns Study (DOPPS). Identifying best practices and 
outcomes in the DOPPS. Semin Dial. févr 2010;23(1):4‑6.  
11.  Schoenfeld D. Partial residuals for the proportional hazards regression model. 
Biometrica. 1982;239‑41.  
12.  Therneau T, Crowson C, Atkinson E. Using Time Dependent Covariates and Time 
Dependent Coefficients in the Cox Model. https://cran.r-
project.org/web/packages/survival/vignettes/timedep.pdf. 2017.  
 12 
13.  Noordzij M, Leffondré K, van Stralen KJ, Zoccali C, Dekker FW, Jager KJ. When do we 
need competing risks methods for survival analysis in nephrology? Nephrol Dial 
Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. nov 2013;28(11):2670‑7.  
14.  Fine J, Gray R. A proportional hazards model for the subdistribution of a competing 
Risk. J Am Stat Assoc. 1999;94:496–509.  
15.  Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, et al. Serum iPTH, calcium 
and phosphate, and the risk of mortality in a European haemodialysis population. 
Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. juin 
2011;26(6):1948‑55.  
16.  Shi Z, Zhen S, Zhou Y, Taylor AW. Hb level, iron intake and mortality in Chinese adults: a 
10-year follow-up study. Br J Nutr. févr 2017;117(4):572‑81.  
17.  Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of 
lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic 
kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled 
trial. Lancet Lond Engl. 25 juin 2011;377(9784):2181‑92.  
18.  Wanner C, Krane V, März W, Olschewski M, Mann JFE, Ruf G, et al. Atorvastatin in 
patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 21 juill 
2005;353(3):238‑48.  
19.  Conroy M, Shannon W. Clinical guidelines: their implementation in general practice. Br 
J Gen Pract. juill 1995;45(396):371‑5.  
20.  Bansal N, Katz R, Robinson-Cohen C, Odden MC, Dalrymple L, Shlipak MG, et al. 
Absolute Rates of Heart Failure, Coronary Heart Disease, and Stroke in Chronic Kidney 
Disease: An Analysis of 3 Community-Based Cohort Studies. JAMA Cardiol. 1 mars 
2017;2(3):314‑8.  
21.  Karamanidou C, Clatworthy J, Weinman J, Horne R. A systematic review of the 
prevalence and determinants of nonadherence to phosphate binding medication in 
patients with end-stage renal disease. BMC Nephrol. 31 janv 2008;9:2.  
22.  Fissell RB, Karaboyas A, Bieber BA, Sen A, Li Y, Lopes AA, et al. Phosphate binder pill 
burden, patient-reported non-adherence, and mineral bone disorder markers: Findings 
from the DOPPS. Hemodial Int Int Symp Home Hemodial. janv 2016;20(1):38‑49.  
23.  Muntner P, Judd SE, Krousel-Wood M, McClellan WM, Safford MM. Low medication 
adherence and hypertension control among adults with CKD: data from the REGARDS 
(Reasons for Geographic and Racial Differences in Stroke) Study. Am J Kidney Dis Off J 
Natl Kidney Found. sept 2010;56(3):447‑57.  
24.  Kliger AS. Quality Measures for Dialysis: Time for a Balanced Scorecard. Clin J Am Soc 
Nephrol CJASN. 5 févr 2016;11(2):363‑8.  
25.  Dekker FW, de Mutsert R, van Dijk PC, Zoccali C, Jager KJ. Survival analysis: time-
dependent effects and time-varying risk factors. Kidney Int. oct 2008;74(8):994‑7.  
 13 
26.  Mendelssohn DC, Pisoni RL, Arrington CJ, Yeates KE, Leblanc M, Deziel C, et al. A 
practice-related risk score (PRS): a DOPPS-derived aggregate quality index for 
haemodialysis facilities. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur 
Ren Assoc. oct 2008;23(10):3227‑33.  
27.  Goldsmith DJA, Covic A, Fouque D, Locatelli F, Olgaard K, Rodriguez M, et al. 
Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic 
Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal 
Best Practice (ERBP) commentary statement. Nephrol Dial Transplant Off Publ Eur Dial 
Transpl Assoc - Eur Ren Assoc. déc 2010;25(12):3823‑31.  
28.  Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO 
clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of 
Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. août 
2009;(113):S1-130.  
29.  Levin NW, Kotanko P, Eckardt K-U, Kasiske BL, Chazot C, Cheung AK, et al. Blood 
pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving 
Global Outcomes controversies conference. Kidney Int. févr 2010;77(4):273‑84.  
30.  Locatelli F, Covic A, Eckardt K-U, Wiecek A, Vanholder R, ERA-EDTA ERBP Advisory 
Board. Anaemia management in patients with chronic kidney disease: a position 
statement by the Anaemia Working Group of European Renal Best Practice (ERBP). 








1. A serum phosphate level between 3.5 and 5.5 mg/dl  
2. An intact PTH level between 150 and 600 pg/ml  
3. A serum calcium level between 8.4 and 10.2 mg/dl  
Hypertension 
(29) 
4. A mean of three blood pressure measurements <140/90 mmHg 
(pre-HD) and <130/80 mmHg (post-HD) 
Anemia (30) 5. A serum hemoglobin level between 11 and 12 g/dl  
Abbreviations: CKD-MBD, chronic kidney disease –mineral and bone disease; HD, hemodialysis; 




Table 2: Demographic characteristics, according to the degree of target attainment 








Age, years (IQR) 67.0 (22.0) 68.0 (21.0) 72.0 (18.0) <0.001 
Male gender, n (%) 1069 (61.1) 2323 (61.1) 448 (58.7) 0.447 
Race (Caucasian), n (%) 1618 (92.4) 3553 (93.4) 727 (95.3) 0.028 
Body mass index, kg/m2 (SD) 25.6 (5.4) 26.0 (5.4) 26.3 (5.1) 0.012 
Smoking (active), n % 221 (12.6) 428 (11.3) 59 (7.7) <0.001 
Time on dialysis, yr (IQR) 0.9 (3.6) 1.7 (4.5) 2.4 (4.7) <0.001 
Single pool Kt/V (SD) 1.5 (0.3) 1.5 (0.3) 1.5 (0.3) 0.011 
Parathyroid hormone pg/ml (IQR) 129 (391) 228 (247) 269 (188) <0.001 
Hemoglobin g/dL (SD) 11.0 (1.7) 11.3 (1.4) 11.5 (0.9) <0.001 
Calcium, g/dL (SD) 8.8 (1.6) 9.0 (1.2) 9.1 (0.7) <0.001 
Phosphate, g/dL (SD) 5.4 (2.1) 4.9 (1.5) 4.6 (0.9) <0.001 
Pre-dialysis systolic BP, mmHg (SD) 146.7 (20.0) 137.0 (21.8) 125.6 (19.5) <0.001 
Pre-dialysis diastolic BP, mmHg (SD) 75.3 (13.6) 71.1 (13.2) 66.7 (11.8) <0.001 
Post-dialysis systolic BP, mmHg (SD) 142.3 (21.1) 132.3 (22.9) 119.6 (19.4) <0.001 
Post-dialysis diastolic BP, mmHg (SD) 74.2 (13.2) 69.9 (13.2) 65.1 (11.6) <0.001 
Diabetes mellitus, n (%) 648 (37.0) 1377 (36.2) 279 (36.6) 0.864 
Cancer (excluding skin), n (%) 317 (18.1) 612 (16.1) 142 (18.6) 0.077 
HIV, n (%) 12 (0.7) 19 (0.5) 2 (0.3) 0.382 
Lung disease, n (%) 226 (12.9) 522 (13.7) 121 (15.9) 0.142 
Psychiatric disorder, n (%) 320 (18.3) 617 (16.2) 143 (18.7) 0.074 
GI bleeding, n (%) 99 (5.7) 187 (4.9) 24 (3.2) 0.028 
Neurological disease, n (%) 221 (12.6) 458 (12.0) 96 (12.6) 0.798 
Recurrent cellulitis, n (%) 170 (9.7) 378 (9.9) 72 (9.4) 0.899 
Hypertension, n (%) 1515 (86.5) 3240 (85.2) 635 (83.2) 0.093 
Antihypertensive medication, n (%)* 1368 (78.1) 2852 (75.0) 519 (68.0) <0.001 
Congestive heart failure, n (%) 311 (17.8) 778 (20.5) 177 (23.2) 0.004 
Cerebrovascular disease, n (%) 288 (16.5) 664 (17.5) 136 (17.8) 0.582 
Coronary heart disease, n (%) 596 (34.0) 1390 (36.6) 300 (39.3) 0.031 
Other cardiovascular diseases, n (%) 463 (26.4) 1242 (32.7) 302 (39.6) <0.001 
Values are percentages for categorical variables. 
Differences in patient characteristics for the target attainment groups were evaluated using χ2 tests for 
categorical variables, ANOVA (analysis of variance) for normally distributed continuous variables and Kruskal-
Wallis test for non-normally distributed continuous variables. 
Mean (SD) for continuous normally distributed variables. 
Median (IQR) for continuous, non-normally distributed variables. 
*Antihypertensive medication included: ACE inhibitors, Angiotensin II receptor blockers, Renin inhibitors, 
Calcium channel blockers, Aldosterone antagonists, Beta blockers, Diuretics, Peripheral adrenergic inhibitors, 
Central-acting alpha 2 antagonists and Vasodilators 
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Table 3: Association between the overall degree of target attainment and mortality during the 
study follow-up period (with moderate attainment as the reference)  
Target attainment 
Time-varying covariates 
Number of events =1328 
 Model 0 Model 1 Model 2 
 HR [95% CI] HR [95% CI] HR [95% CI] 
Low attainment 1.64 [1.46, 1.85] 1.18 [1.05, 1.33] 1.19 [1.06, 1.34] 
Moderate attainment Reference Reference Reference 
High attainment 0.67 [0.56, 0.81] 0.82 [0.68, 0.99] 0.82 [0.68, 0.99] 
 
Model 0: unadjusted 
Model 1: adjusted for age, gender, race, country, time on dialysis, smoking, body mass index, single 
pool Kt/V  
Model 2: additionally adjusted for 13 comorbid diseases (diabetes mellitus, cancer (excluding skin), 
HIV, lung disease, psychiatric disorders, gastrointestinal bleeding, neurological disease, recurrent 
cellulitis, hypertension, congestive heart failure, cerebrovascular disease, coronary heart disease, and 
















Table 4: Association between the overall degree of target attainment and hospitalization during 




Number of events = 3695 
 Model 0 Model 1 Model 2 
 HR [95% CI] HR [95% CI] HR [95% CI] 
Low attainment 3.13 [2.94, 3.33] 1.07 [0.97, 1.19] 1.08 [0.97, 1.19] 
Moderate attainment Reference Reference Reference 
High attainment 0.84 [0.75, 0.94] 1.13 [0.99, 1.30] 1.13 [0.99, 1.30] 
 
Model 0: unadjusted 
Model 1: adjusted for age, gender, race, country, time on dialysis, smoking, body mass index, single 
pool Kt/V  
Model 2: additionally adjusted for 13 comorbid diseases (diabetes mellitus, cancer (excluding skin), 
HIV, lung disease, psychiatric disorders, gastrointestinal bleeding, neurological disease, recurrent 
cellulitis, hypertension, congestive heart failure, cerebrovascular disease, coronary heart disease, and 





Supplementary Table 1: Association between the overall degree of target attainment and mortality 
during the study follow-up period (with low attainment as the reference) 
Target attainment 
Time-varying covariates 
Number of events = 1328 
 Model 0 Model 1 Model 2 
 HR [95% CI] HR [95% CI] HR [95% CI] 
Low attainment Reference Reference Reference 
Moderate attainment 0.61 [0.54, 0.68] 0.85 [0.75, 0.95] 0.84 [0.75, 0.95] 
High attainment 0.41 [0.34, 0.50] 0.70 [0.57, 0.85] 0.69 [0.56, 0.84] 
 
Model 0: unadjusted 
Model 1: adjusted for age, gender, race, country, time on dialysis, smoking, body mass index, single 
pool Kt/V  
Model 2: additionally adjusted for 13 comorbid diseases (diabetes mellitus, cancer (excluding skin), 
HIV, lung disease, psychiatric disorders, gastrointestinal bleeding, neurological disease, recurrent 
cellulitis, hypertension, congestive heart failure, cerebrovascular disease, coronary heart disease, and 





Supplementary Table 2: Association between the attainment of individual targets and mortality 
Number of events=1328. 
Target attainment Model 0 Model 1 Model 2 Model 3 
  HR [95% CI] HR [95% CI] HR [95% CI] 
PTH on target (150≤PTH<600) Reference Reference Reference Reference 
Hypoparathyroidism (PTH<150) 1.57 [1.36, 1.81] 1.32 [1.15, 1.53] 1.29 [1.12, 1.49] 1.22 [1.06, 1.42] 
Hyperparathyroidism (PTH≥600) 3.30 [2.90, 3.75] 1.34 [1.18, 1.53] 1.38 [1.21, 1.57] 1.43 [1.25, 1.63] 
Phosphate on target 
(3.5≤PO4<5.5) 
Reference Reference Reference Reference 
Hypophosphatemia (PO4<3.5) 1.56 [1.36, 1.78] 1.37 [1.20, 1.58] 1.31 [1.14, 1.50] 1.15 [0.99, 1.32] 
Hyperphosphatemia (PO4≥5.5) 1.19 [1.05, 1.34] 1.08 [0.95, 1.23] 1.09 [0.96, 1.24] 1.09 [0.95, 1.25] 
Calcium on target (8.4≤Ca<10.2) Reference Reference Reference Reference 
Hypocalcemia (Ca<8.4) 1.50 [1.30, 1.72] 1.61 [1.39, 1.85] 1.54 [1.34, 1.78] 1.38 [1.19, 1.59] 
Hypercalcemia (Ca≥10.2) 1.64 [1.43, 1.88] 1.14 [0.99, 1.31] 1.13 [0.98, 1.30] 1.19 [1.03, 1.38] 
Hemoglobin (Hb) on target (11 ≤ 
Hb <12) 
Reference Reference Reference Reference 
Hb <9 3.56 [2.96, 4.28] 2.57 [2.13, 3.10] 2.44 [2.02, 2.95] 2.19 [1.81, 2.65] 
9 ≤ Hb < 11 1.67 [1.45, 1.93] 1.51 [1.31, 1.75] 1.50 [1.30, 1.73] 1.46 [1.26, 1.69] 
12 ≤ Hb < 13 g/dl 0.80 [0.67, 0.96] 0.80 [0.67, 0.96] 0.82 [0.69, 0.99] 0.81 [0.68, 0.98] 
Hb ≥ 13 g/d 1.14 [0.95, 1.38] 0.84 [0.70, 1.02] 0.85 [0.70, 1.02] 0.79 [0.65, 0.96] 
Blood pressure on target Reference Reference Reference Reference 
Hypertension (pre-dialysis 
systolic ≥140 or pre-dialysis 
diastolic ≥90 or post-dialysis 
systolic ≥130 or post-dialysis 
diastolic ≥80 
0.77 [0.69, 0.86] 0.68 [0.61, 0.76] 0.71 [0.63, 0.79] 0.74 [0.66, 0.83] 
 
Model 0: Unadjusted 
Model 1: adjusted for age, gender, race, country, time on dialysis, smoking, body mass index, single 
pool kt/V  
Model 2: additionally adjusted for 13 comorbid diseases 
Model 3: additionally adjusted for each target 
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Supplementary Table 3: Association between the overall degree of target attainment (excluding 
blood pressure target) and mortality during the study follow-up period (with moderate attainment 
as the reference)  
Target attainment 
Time-varying covariates 
Number of events = 1328 
 Model 0 Model 1 Model 2 
 HR [95% CI] HR [95% CI] HR [95% CI] 
Low attainment 1.96 [1.75, 2.18] 1.38 [1.23, 1.54] 1.35 [1.21, 1.51] 
Moderate attainment Reference Reference Reference 
High attainment 0.51 [0.36, 0.73] 0.68 [0.47, 0.97] 0.70 [0.49, 1.00] 
 
Model 0: unadjusted 
Model 1: adjusted for age, gender, race, country, time on dialysis, smoking, body mass index, single 
pool Kt/V  
Model 2: additionally adjusted for 13 comorbid diseases (diabetes mellitus, cancer (excluding skin), 
HIV, lung disease, psychiatric disorders, gastrointestinal bleeding, neurological disease, recurrent 
cellulitis, hypertension, congestive heart failure, cerebrovascular disease, coronary heart disease, and 




Supplementary Table 4: Association between attainment of individual targets and first 
hospitalization using a competitive risk model. Number of events: 3695  
Target attainment Model 0 Model 1 Model 2 Model 3 
  HR [95% CI] HR [95% CI] HR [95% CI] 
PTH on target (150≤PTH<600) Reference Reference Reference Reference 
Hypoparathyroidism (PTH<150) 1.01 [0.93, 1.11] 0.84 [0.75, 0.95] 0.84 [0.74, 0.94] 0.85 [0.75, 0.96] 
Hyperparathyroidism (PTH≥600) 3.43 [3.19, 3.68] 0.80 [0.72, 0.89] 0.80 [0.72, 0.89] 0.67 [0.59, 0.75] 
Phosphate on target 
(3.5≤PO4<5.5) 
Reference Reference Reference Reference 
Hypophosphatemia (PO4<3.5) 1.02 [0.92, 1.14] 0.95 [0.82, 1.10] 0.95 [0.82, 1.10] 0.97 [0.84, 1.12] 
Hyperphosphatemia (PO4≥5.5) 2.61 [2.45, 2.79] 1.10 [0.99, 1.22] 1.11 [1.00, 1.22] 1.03 [0.93, 1.14] 
Calcium on target (8.4≤Ca<10.2) Reference Reference Reference Reference 
Hypocalcemia (Ca<8.4) 1.04 [0.94, 1.15] 1.08 [0.93, 1.26] 1.10 [0.95, 1.28] 1.10 [0.95, 1.27] 
Hypercalcemia (Ca≥10.2) 3.95 [3.67, 4.25] 1.27 [1.13, 1.41] 1.28 [1.15, 1.43] 1.27 [1.13, 1.44] 
Hemoglobin (Hb) on target (11 ≤ 
Hb <12) 
Reference Reference Reference Reference 
Hb <9 1.35 [1.11, 1.64] 0.79 [0.59, 1.06] 0.81 [0.61, 1.09] 0.88 [0.66, 1.17] 
9 ≤ Hb < 11 1.09 [0.98, 1.20] 0.91 [0.80, 1.04] 0.92 [0.81, 1.05] 0.93 [0.82, 1.06] 
12 ≤ Hb < 13 g/dl 0.97 [0.87, 1.07] 0.93 [0.81, 1.06] 0.93 [0.81, 1.06] 0.93 [0.81, 1.06] 
Hb ≥ 13 g/d 3.87 [3.57, 4.21] 1.16 [1.02, 1.32] 1.18 [1.04, 1.33] 1.18 [1.03, 1.35] 
Blood pressure on target Reference Reference Reference Reference 
Hypertension (pre-dialysis 
systolic ≥140 or pre-dialysis 
diastolic ≥90 or post-dialysis 
systolic ≥130 or post-dialysis 
diastolic ≥80 
1.99 [1.85, 2.13] 1.15 [1.04, 1.27] 1.14 [1.03, 1.27] 1.07 [0.97, 1.19] 
 
Model 0: unadjusted 
Model 1: adjusted for age, gender, race, country, time on dialysis, smoking, body mass index, single 
pool Kt/V  
Model 2: additionally adjusted for 13 comorbid diseases (diabetes mellitus, cancer (excluding skin), 
HIV, lung disease, psychiatric disorders, gastrointestinal bleeding, neurological disease, recurrent 
cellulitis, hypertension, congestive heart failure, cerebrovascular disease, coronary heart disease, and 
other cardiovascular diseases). 
Model 3: additionally adjusted for each target  
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Supplementary Table 5: Association between the overall degree of target attainment and 
hospitalization during the study follow-up period (with low attainment as the reference), using a 
competiting risk model. 
Target attainment 
Time-varying covariates 
Number of events = 1328 
 Model 0 Model 1 Model 2 
 HR [95% CI] HR [95% CI] HR [95% CI] 
Low attainment Reference Reference Reference 
Moderate attainment 0.32 [0.30, 0.34] 0.93 [0.84, 1.03] 0.93 [0.84, 1.03] 
High attainment 0.27 [0.24, 0.30] 1.06 [0.91, 1.23] 1.05 [0.90, 1.22] 
 
Model 0: unadjusted 
Model 1: adjusted for age, gender, race, country, time on dialysis, smoking, body mass index, single 
pool Kt/V  
Model 2: additionally adjusted for 13 comorbid diseases (diabetes mellitus, cancer (excluding skin), 
HIV, lung disease, psychiatric disorders, gastrointestinal bleeding, neurological disease, recurrent 
cellulitis, hypertension, congestive heart failure, cerebrovascular disease, coronary heart disease, and 
other cardiovascular diseases). 
